Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.-论文-万方医学网

作者： B,Vincenzi ^[1] ; S,Galluzzo ^[2] ; D,Santini ^[1] ; L,Rocci ^[1] ; F,Loupakis ^[3] ; P,Correale ^[4] ; R,Addeo ^[5] ; A,Zoccoli ^[1] ; A,Napolitano ^[1] ; F,Graziano ^[6] ; A,Ruzzo ^[7] ; A,Falcone ^[4] ; G,Francini ^[5] ; G,Dicuonzo ^[8] ; G,Tonini ^[1]

作者单位： Department of Medical Oncology, University Campus Bio-Medico, Rome. ^[1] Department of Medical Oncology, University Campus Bio-Medico, Rome. Electronic address: s.galluzzo@unicampus.it. ^[2] Unit of Medical Oncology, Azienda-Ospedaliero Universitaria Pisana, University of Pisa, Pisa. ^[3] Section of Medical Oncology, Department "Giorgio Segre" of Pharmacology, University of Siena, Siena. ^[4] Oncology Department, "S. Giovanni di Dio" Hospital, Frattaminore. ^[5] Unit of Medical Oncology, Hospital of Pesaro, Pesaro. ^[6] Section of Biochemistry and Molecular Biology "G. Fornaini", Department of Biomolecular Sciences, University of Urbino, Urbino. ^[7] Laboratory Medicine, University Campus Bio-Medico, Rome, Italy. ^[8]

主题词腺癌(Adenocarcinoma);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);喜树碱(Camptothecin);结直肠肿瘤(Colorectal Neoplasms);无病生存(Disease-Free Survival);女(雌)性(Female);基因型(Genotype);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);镁(Magnesium);男(雄)性(Male);中年人(Middle Aged);多元分析(Multivariate Analysis);肿瘤分期(Neoplasm Staging);原癌基因蛋白质类(Proto-Oncogene Proteins);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));回顾性研究(Retrospective Studies);ras蛋白质类(ras Proteins)

DOI 10.1093/annonc/mdq550

PMID 21115601

发布时间 2022-04-19

检索历史清除

Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.

Annals of oncology

相似文献

Annals of oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.

Annals of oncology

相似文献

Annals of oncology

相关期刊

检索历史清除